BR0213977A - Derivados de piridina como ligantes de receptores de nmda - Google Patents
Derivados de piridina como ligantes de receptores de nmdaInfo
- Publication number
- BR0213977A BR0213977A BR0213977-4A BR0213977A BR0213977A BR 0213977 A BR0213977 A BR 0213977A BR 0213977 A BR0213977 A BR 0213977A BR 0213977 A BR0213977 A BR 0213977A
- Authority
- BR
- Brazil
- Prior art keywords
- hydrogen
- lower alkyl
- nmda receptor
- pyridine derivatives
- compounds
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01126467 | 2001-11-09 | ||
| PCT/EP2002/012240 WO2003040128A1 (en) | 2001-11-09 | 2002-11-02 | Pyridine derivatives as nmda receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0213977A true BR0213977A (pt) | 2004-08-31 |
Family
ID=8179179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0213977-4A BR0213977A (pt) | 2001-11-09 | 2002-11-02 | Derivados de piridina como ligantes de receptores de nmda |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6831087B2 (enExample) |
| EP (1) | EP1448547B1 (enExample) |
| JP (1) | JP4188837B2 (enExample) |
| KR (1) | KR100589995B1 (enExample) |
| CN (1) | CN100516061C (enExample) |
| AR (1) | AR037221A1 (enExample) |
| AT (1) | ATE293619T1 (enExample) |
| AU (1) | AU2002351816B8 (enExample) |
| BR (1) | BR0213977A (enExample) |
| CA (1) | CA2467973C (enExample) |
| DE (1) | DE60203820T2 (enExample) |
| ES (1) | ES2240829T3 (enExample) |
| MX (1) | MXPA04004308A (enExample) |
| PL (1) | PL369544A1 (enExample) |
| RU (1) | RU2303037C2 (enExample) |
| WO (1) | WO2003040128A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007008816A (ja) * | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
| US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| RU2320654C1 (ru) * | 2006-05-24 | 2008-03-27 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) | 2,2-ДИМЕТИЛ-4-(4,6-ДИМЕТИЛ-2-ПИРИДОН-3-ИЛ)-1,2-ДИГИДРО-БЕНЗО[f]ИЗОХИНОЛИНА ГИДРОХЛОРИД, ПРОЯВЛЯЮЩИЙ ПРЯМОЕ АНТИКОАГУЛЯНТНОЕ ДЕЙСТВИЕ |
| US8722929B2 (en) * | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
| US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| US8563566B2 (en) * | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| MX2010003849A (es) | 2007-10-18 | 2010-04-27 | Boehringer Ingelheim Int | Antagonistas de cgrp. |
| EP2225237A2 (de) * | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| EP2225223B1 (de) | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| EP2062889A1 (de) * | 2007-11-22 | 2009-05-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbindungen |
| EA014100B1 (ru) * | 2008-02-21 | 2010-08-30 | Общество С Ограниченной Ответственностью "Валексфарм" | Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения |
| RU2438672C1 (ru) | 2010-04-30 | 2012-01-10 | Общество с ограниченной ответственностью "Клевер Фарм" | Агент, проявляющий свойства активатора когнитивных функций (варианты) |
| WO2025124571A1 (zh) * | 2023-12-14 | 2025-06-19 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| AU4500399A (en) * | 1998-05-25 | 1999-12-13 | Basf Aktiengesellschaft | New heterocyclically substituted amides, their production and their use |
| US6440995B1 (en) * | 1999-10-01 | 2002-08-27 | Hoffman-La Roche Inc. | Quinolin-4-yl derivatives |
| EP1088818B1 (en) | 1999-10-01 | 2004-11-03 | F. Hoffmann-La Roche Ag | Quinolin-4-yl derivatives |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
-
2002
- 2002-10-29 US US10/282,365 patent/US6831087B2/en not_active Expired - Fee Related
- 2002-11-02 BR BR0213977-4A patent/BR0213977A/pt not_active IP Right Cessation
- 2002-11-02 AT AT02787541T patent/ATE293619T1/de not_active IP Right Cessation
- 2002-11-02 CA CA002467973A patent/CA2467973C/en not_active Expired - Fee Related
- 2002-11-02 AU AU2002351816A patent/AU2002351816B8/en not_active Ceased
- 2002-11-02 EP EP02787541A patent/EP1448547B1/en not_active Expired - Lifetime
- 2002-11-02 PL PL02369544A patent/PL369544A1/xx unknown
- 2002-11-02 ES ES02787541T patent/ES2240829T3/es not_active Expired - Lifetime
- 2002-11-02 DE DE60203820T patent/DE60203820T2/de not_active Expired - Lifetime
- 2002-11-02 WO PCT/EP2002/012240 patent/WO2003040128A1/en not_active Ceased
- 2002-11-02 MX MXPA04004308A patent/MXPA04004308A/es active IP Right Grant
- 2002-11-02 CN CNB028222512A patent/CN100516061C/zh not_active Expired - Fee Related
- 2002-11-02 JP JP2003542174A patent/JP4188837B2/ja not_active Expired - Fee Related
- 2002-11-02 RU RU2004117595/04A patent/RU2303037C2/ru not_active IP Right Cessation
- 2002-11-02 KR KR1020047007031A patent/KR100589995B1/ko not_active Expired - Fee Related
- 2002-11-06 AR ARP020104227A patent/AR037221A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20030119870A1 (en) | 2003-06-26 |
| US6831087B2 (en) | 2004-12-14 |
| CN100516061C (zh) | 2009-07-22 |
| PL369544A1 (en) | 2005-05-02 |
| DE60203820D1 (de) | 2005-05-25 |
| ES2240829T3 (es) | 2005-10-16 |
| RU2004117595A (ru) | 2006-01-10 |
| DE60203820T2 (de) | 2006-02-23 |
| AR037221A1 (es) | 2004-10-27 |
| CA2467973A1 (en) | 2003-05-15 |
| AU2002351816B8 (en) | 2008-04-03 |
| CN1585762A (zh) | 2005-02-23 |
| AU2002351816B2 (en) | 2008-03-06 |
| ATE293619T1 (de) | 2005-05-15 |
| MXPA04004308A (es) | 2004-08-11 |
| EP1448547A1 (en) | 2004-08-25 |
| WO2003040128A1 (en) | 2003-05-15 |
| EP1448547B1 (en) | 2005-04-20 |
| JP2005513004A (ja) | 2005-05-12 |
| JP4188837B2 (ja) | 2008-12-03 |
| KR20050042252A (ko) | 2005-05-06 |
| CA2467973C (en) | 2009-09-01 |
| RU2303037C2 (ru) | 2007-07-20 |
| KR100589995B1 (ko) | 2006-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0213977A (pt) | Derivados de piridina como ligantes de receptores de nmda | |
| BR0210538A (pt) | Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7 | |
| ES2193362T3 (es) | Derivados de 2-pirimidinamina y su procedimiento de preparacion de los mismos. | |
| DK0870768T3 (da) | Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler | |
| Lumma Jr et al. | Rational design of 4-[(methylsulfonyl) amino] benzamides as class III antiarrhythmic agents | |
| FI92582B (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten kinoksaliinijohdannaisten valmistamiseksi | |
| FI905770A0 (fi) | Uusia isoindolonijohdannaisia niiden valmistus ja käyttö | |
| ATE266013T1 (de) | 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4) | |
| BR0011097A (pt) | Derivados de 5-fenil-piridina | |
| BR0311593A (pt) | Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc | |
| NO973243L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av gynekologiske sykdommer | |
| HUP9901616A1 (hu) | Új benzofuranon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| NO20040589L (no) | Arylsulfonylderivater med 5-HT6 reseptor affinitet. | |
| BRPI0518068A (pt) | composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada | |
| HUP0102057A2 (hu) | Benzofuroxánszármazékok alkalmazása angina pectoris kezelésében | |
| BR0115480A (pt) | Derivados de pirimidina | |
| NO992676L (no) | 1,4-diazabicyklo[2,2,2]okt-2-ylmetylderivater, deres fremstilling og terapeutiske anvendelse | |
| Meyer et al. | Synthesis and In Vitro Evaluation of 2‐Aminoquinazolin‐4 (3H)‐one‐Based Inhibitors for tRNA‐Guanine Transglycosylase (TGT) | |
| BR0214488A (pt) | Derivados de benzotiazol | |
| NZ519126A (en) | Novel IL-8 receptor antagonists | |
| WO2000075150A1 (fr) | Ligands du recepteur ip¿3? | |
| Fierro et al. | Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: Insights from molecular modeling studies | |
| ATE219486T1 (de) | Trizyklische indol-2-carbonsäure derivate als selektive nmda rezeptor antagonisten | |
| DK420979A (da) | Fremgangsmaade til fremstilling af isatinderivater | |
| BR0107404A (pt) | Derivados de indol que atuam como antagonistas do receptor mcp-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUI DADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE. |